With a large number of mid-sized and large-cap med-tech companies
outperforming the market over the last three months, it's fair to ask
how much of Boston Scientific's (BSX) performance is based on real conviction that the company has turned the corner and how much is based on a sector-wide
and market-wide melt-up. Fourth-quarter earnings and management
guidance give cause for optimism that Boston Scientific is finally
moving past its problems, but investors should not forget the
difficulties that come with trying to play catch-up in a fiercely
competitive market.
Click the link to continue:
Is It Finally The Right Time For Boston Scientific?
No comments:
Post a Comment